PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders.

Adenosine A receptor (AR) antagonists have emerged as complementary non-dopaminergic drugs to alleviate Parkinson's disease (PD) symptomatology. Here, we characterize a novel non-xhantine non-furan AR antagonist, PBF509, as a potential pro-dopaminergic drug for PD management. First, PBF509 was shown to be a highly potent ligand at the human AR, since it antagonized AR agonist-mediated cAMP accumulation and impedance responses with K values of 72.